Abstracts tagged "immunology"

Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: 0008 • ACR Convergence 2025
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Maria Cecilia Ramello², Agustin Plasencia², Jordan Anderson², Tobias Green², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
Abstract Number: 0781 • ACR Convergence 2025
Comprehensive mass cytometry analyses of disease-related cells in adult-onset Still’s disease
Hiroto Yoshida¹, Mayu Magi¹, Hiroya Tamai², Kotaro Matsumoto², Keiko Yoshimoto², Tetsuhiro Soeda¹ and Yuko Kaneko², ¹Chugai Pharmaceutical Co., Ltd. Product Research Dept., Yokohama, Kanagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Adult-onset Still's Disease (AOSD) is a rare autoinflammatory disorder characterized by high fever, rash, and arthritis. Although overactivation of macrophages, an increase in specific…
Abstract Number: 0899 • ACR Convergence 2025
Altered B cell Subsets Shared in Immune Checkpoint Inhibitor Associated Sicca Syndrome and Sjogren’s Disease
Caroline Atlas¹, Balakrishnan Kamaraj¹, Omid Jamshidi¹, Adam Mor¹, Yevgeniya Gartshteyn², Teja Kapoor³ and Robert Winchester¹, ¹Columbia University, New York, NY, ²Columbia University Medical Center, Glen Rock, NJ, ³Columbia University Irving Medical Center, New York, NY
Background/Purpose: Sicca symptoms may develop in the setting of immune checkpoint inhibitor (ICI) therapy and are clinically indistinguishable from those encountered in Sjogren’s disease (SjD).…
Abstract Number: 1004 • ACR Convergence 2025
Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Yang Yang¹, Yusuke Miyashita², Madison Mangin³, Kellen Winden¹, Peter Nigrovic² and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We…
Abstract Number: 1339 • ACR Convergence 2025
Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors
Romain Stammler¹, Peter Chen², Orianne Debeaupuis², Lin Pierre Zhao¹, Mirabelle Ruyer Thompson¹, Eve Zakine¹, Julien Rossignol¹, Lauriane Goldwirt¹, Thibault Comont³, Mael Heiblig⁴, Lionel Ades¹, Marie Sebert¹, Jean-sébastien Allain⁵, Julien Campagne⁶, Marie Anne Couturier⁷, Marina Cumin⁸, Marie Caroline Dalmas⁹, Guillaume Denis¹⁰, Cecile Devloo¹¹, Adrien De Voeght¹², Louis Drevon¹, Pierre Duffau¹³, Sophie georgin-Lavialle¹⁴, Delphine Gobert¹, Noemie Abisror¹⁵, Olivier Kosmider¹⁶, Fréderic Rieux-Laucat², Estibaliz LAZARO¹⁷, Jean Guillaume Lopez¹⁸, Alexandre Maria¹⁹, Wladimir Mauhin²⁰, Julie Merindol²¹, Claire Merlot²², Tristan Mirault¹, Laurent Pascal²³, François Perrin²⁴, Emmanuel Raffoux¹, Ramy Rahme²⁵, Damien Roos-Weil¹, Benjamin Terrier²⁶, Benjamin Torreau²⁷, Olivier Fain¹, Pierre Fenaux¹, Pierre Hirsch¹, Vincent Jachiet¹, Jerome Hadjadj¹ and Arsène Mekinian²⁸, ¹Assistance Publique des Hôpitaux de Paris, Paris, France, ²Imagine Institute, Paris, France, ³Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Scorff-Lorient Hospital, Lorient, France, ⁶Hospital Robert Schuman, Metz, France, ⁷Centre Hospitalier Régional et Universitaire de Brest, Brest, France, ⁸Centre hospitalier de Libourne, Libourne, France, ⁹Strasbourg University Hospital Center, Strasbourg, France, ¹⁰Centre Hospitalier Rochefort, Rochefort, France, ¹¹Centre hospitalier de Dieppe, Dieppe, France, ¹²CHU of Liège, Liège, Belgium, ¹³Groupe Hospitalier Saint-André, Bordeaux, France, ¹⁴Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁵Internal Medicine, CHU Saint-Antoine,, Paris, France, ¹⁶AP-HP, Hopital Cochin, Institut Cochin, CNRS UMR⁸¹⁰⁴, INSERM U¹⁰¹⁶ Université Paris Cité Paris France., PARIS, France, ¹⁷Bordeaux University Hospital, Pessac, France, ¹⁸Dupuytren University Hospital, Limoges, France, ¹⁹Saint-Eloi Hospital, Montpellier, France, ²⁰Croix Saint Simon Hospital, Paris, France, ²¹University Hospital of Nice, Nice, France, ²²Centre hospitaliser d’Orléans, Orléans, France, ²³Hôpital Saint-Vincent de Paul, Lille, France, ²⁴Centre Hospitalier de Saint-Nazaire, Saint Nazaire, France, ²⁵Assistance Publique des Hôpitaux de Paris, Bobigny, France, ²⁶Cochin Hospital, Paris, France, ²⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ²⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France
Background/Purpose: Clonal hematopoiesis has emerged as a key contributor to systemic inflammation, bridging hematologic and immune-mediated inflammatory disorders (IMIDs). Isocitrate dehydrogenase 1 and 2 (IDH1/2)…
Abstract Number: 1773 • ACR Convergence 2025
Redefining disease activity assessment in IgG4-Related Disease: The role of classical and novel biomarkers
Marta López¹, rafeal Benito-Melero², Laura Martinez-Martinez³, Hye Sang-Park⁴, sara Calleja³, Helena Codes Mendez⁵, Mar Concepción Martín³, Berta Magallares³, Ivan Castellví⁶, Ana Laiz⁵, Cesar Diaz³ and Hector Corominas⁷, ¹Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ²MD, barcelona, Spain, ³Hospital Santa Creu i Sant Pau, Barcelona, Spain, ⁴Hospital Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁵Sant Pau Hospital, Barcelona, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ⁷Hospital de Sant Pau, Barcelona, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disorder characterized by elevated serum IgG4 levels and tissue infiltration by IgG4-positive plasma cells. Despite advances in…
Abstract Number: 2277 • ACR Convergence 2025
Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis
John Bui¹, Jason Dubovsky², Jennifer Abrams³, Sara Charmsaz⁴, Michelle Blake¹, Joshua Beilke⁴, Anne-Renee van der Vuurst de Vries¹, Joseph Arron⁵, Jonathan Graf⁶ and Jeffrey Bluestone⁷, ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, South San Francisco, ³Sonomabio, San Francisco, CA, ⁴Sonoma Biotherapeutics, Seattle, ⁵Sonoma Biotherapeutics, San Francisco, CA, ⁶UCSF, San Francisco, CA, ⁷Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Emerging cell-based therapies for rheumatoid arthritis (RA) target the underlying immunologic activity of disease. Objective biomarkers to-date are downstream sequelae of RA immunologic drivers.…
Abstract Number: 2682 • ACR Convergence 2025
Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
Ana C Medeiros-Ribeiro¹, Lucas Farias², Nadia Emi Aikawa³, Sandra G Pasoto¹, Leonard V Kupa², Carla Saad¹, Andrea Shimabuco², Karina Bonfiglioli⁴, Diogo Domiciano⁴, Andre Franco⁴, Clovis Artur Silva⁵ and Eloisa Bonfa⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵University of São Paulo, São Paulo, São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil
Background/Purpose: The recombinant vaccine against herpes zoster (HZ) (RZV) is recommended by ACR and EULAR for immunocompromised individuals. Short-term observational data from RA cohorts aged…
Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Adam Cartwright¹, Lucas Gyger¹, Foram Desai², Shailee Vora², Anna Kostikova¹, Xudong Wang², Peter Trenh², Katie May², Sophia Nguyen², Chris King², Daniel Lam², Xavi Lucas¹, Mary Zlotosch², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Debora Bonenfant¹, Sharon Townson², Eswar Krishnan², Filip Janku², John Castle¹, Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…
Abstract Number: 0782 • ACR Convergence 2025
Expansion of T-bet⁺ Age-Associated B Cells Is Associated with Clinical Complications in Still’s Disease
Krisztian Csomos¹, Boglarka Ujhazi¹, Mariana Correia Marques², Emily Rosenbaum¹ and Michael Ombrello³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ²Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Still’s disease is a rare and severe autoinflammatory disorder characterized by daily spiking fevers, arthritis, an evanescent rash, and prominent systemic features, including lymphadenopathy,…
Abstract Number: 0902 • ACR Convergence 2025
A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture
Deisy Muriel Velez arteaga¹, Yemil Atisha Fregoso², Hasret Gunduz³ and Betty Diamond⁴, ¹The Elmezzi School of Molecular Medicine, New Rochelle, NY, ²The Feinstein Institute, Long Island, NY, ³The Feinstein Institute, Long Island, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Studying antinuclear antibody (ANA) producing B cells at the single-cell level offers critical insights into their fine specificity and functional characteristics. However, conventional techniques…
Abstract Number: 1090 • ACR Convergence 2025
Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Amelia Khoo and Anokhi Saklecha, Yale University, New Haven, CT
Background/Purpose: Rituximab, a monoclonal antibody which binds to the CD20 antigen of B cells, is used in the treatment of many rheumatologic conditions. Due to…
Abstract Number: 1400 • ACR Convergence 2025
Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
Renata Fróes Ramos de Lima¹, Regis Sewa Marques², Zoraida Sachetto³ and Alisson Pugliesi⁴, ¹Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil, ²Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil, ³UNIVERSIDADE ESTADUAL DE CAMPINAS, UNICAMP, Campinas, Sao Paulo, Brazil, ⁴Unicamp, Campinas, Brazil
Background/Purpose: Sjogren’s disease (SjD) is a systemic autoimmune disorder characterized by inflammatory involvement of the exocrine glands and extra-glandular manifestations. Among the latter, there is…

1
2
3
…
33
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].